Skip to content

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Why Subscribe
About Us
Accreditation
Library
Live Events
Sign Up / Login

Library

By pinki shah / May 14, 2022

Speciality

Author / Speaker

Title of Presentation

Type of Media

Event

2024 Event

Clear

Displaying 976 - 1,000 of 2,711

«
1
…
38
39
40
41
42
…
109
»

Anticoagulation in the Oncology Patient

Anticoagulation in the Oncology Patient

By: Pamela Dudkiewicz, ARPN

MDS: State of the Art

MDS: State of the Art

By: Paul Koller, MD

Myelodysplasia: Biomarkers, Risk Assessment and Novel Treatments

Myelodysplasia: Biomarkers, Risk Assessment and Novel Treatments

By: Rami Komrokji, MD

Hematology Session I

Hematology Session I

By: Rami Komrokji, Mohamed Kharfan-Dabaja, Guillermo Garcia-Manero

Hematology Session II

Hematology Session II

By: Sikander Ailawadhi, Javier Pinilla-Ibarz, Lisa Welsh

Waldenstrom’s Macroglobulinemia

Waldenstrom’s Macroglobulinemia

By: Steven P. Treon, MD, PhD, ,FACP, FRCP

Waldenstrom’s Macroglobulinemia

Waldenstrom’s Macroglobulinemia

By: Steven P. Treon, MD, PhD, ,FACP, FRCP

Management of Immune Related Adverse Events

Management of Immune Related Adverse Events

By: Alicia Rigby, AOCNP

Management of Immune Related Adverse Events

Management of Immune Related Adverse Events

By: Alicia Rigby, RN, MSN, FNP, AOCNP

Management of Immune Related Adverse Events

Management of Immune Related Adverse Events

By: Alicia Rigby, RN, MSN, FNP, AOCNP

Advances in Immunotherapy

Advances in Immunotherapy

By: Arta M Monjazeb - MD - PhD

Systemic Immunotherapy Combinations

Systemic Immunotherapy Combinations

By: Arta M Monjazeb, MD, PhD

Advances in Immunotherapy

Advances in Immunotherapy

By: Arta M. Monjazeb, MD, PhD

Immunotherapy in Non-Melanoma Skin Cancers (BCC, Squamous & Merkel) and What After IO Failure?

Immunotherapy in Non-Melanoma Skin Cancers (BCC, Squamous & Merkel) and What After IO Failure?

By: Belisario Arango, MD

Immunotherapy in Non-Melanoma Skin Cancers (BCC, Squamous & Merkel) and What After IO Failure?

Immunotherapy in Non-Melanoma Skin Cancers (BCC, Squamous & Merkel) and What After IO Failure?

By: Belisario Arango, MD

Overcoming T-Cell Exhaustion

Overcoming T-Cell Exhaustion

By: Brian S. Henick, MD

Overcoming T-Cell Exhaustion

Overcoming T-Cell Exhaustion

By: Brian S. Henick, MD

New Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue?

New Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue?

By: Bruna Pellini, MD

New Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue?

New Platforms and Developments of Immunotherapy Biomarkers Beyond PD-L1 in Tissue?

By: Bruna Pellini, MD

Combined Angio-CT system – Precision therapy in IO

Combined Angio-CT system – Precision therapy in IO

By: Bruno Odisio, MD

Precision Imaging in IO

Precision Imaging in IO

By: Chiara Floridi, MD

Novel Frontiers in the Use of ctDNA in Oncology

Novel Frontiers in the Use of ctDNA in Oncology

By: Christian Rolfo, MD, PhD, MBA, Dr.hc

Biomarkers for Perioperative Immunotherapy?

Biomarkers for Perioperative Immunotherapy?

By: David Carbone, MD

The New Role of Microbiome in Lung Cancer Immunotherapy

The New Role of Microbiome in Lung Cancer Immunotherapy

By: David Carbone, MD

Biomarkers for Perioperative Immunotherapy?

Biomarkers for Perioperative Immunotherapy?

By: David Carbone, MD

«
1
…
38
39
40
41
42
…
109
»

Post navigation

← Previous View

© 2024 MEC Inc. All rights reserved | Digital Marketing by Katapult Marketing

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok